# Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

> **NCT06947993** · PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 224 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** GHZ339
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06947993
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-16
- **Primary completion:** 2028-11-27
- **Final completion:** 2028-12-22
- **Target enrollment:** 224 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06947993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06947993, "Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06947993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*